Сравнение
BPC-157 vs. Thymosin Beta-4
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Заживление
Заживление
Номер CAS
137525-51-0
77591-33-4
Молекулярная масса
1419.5 g/mol
4921 g/mol
Период полувыведения
4 h
нет данных
Последовательность
GEPPPGKPADDAGLVAc-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESМеханизм действия
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Thymosin Beta-4
Thymosin Beta-4 forms a 1:1 complex with monomeric (G-)actin and is regarded as the principal actin-sequestering factor in many cell types, thereby influencing cytoskeletal dynamics and directional cell migration. Preclinical models additionally describe effects on endothelial cell migration and neovascularisation, as well as activation of survival signalling pathways (including ILK/Akt). The mechanistic evidence derives predominantly from cell-culture and animal models.
Доказательная база
Наивысшая доказательность
Модель на животных
Исследование на людях
Исследования
5
4
из них на людях
0
1
Зафиксированные эффекты
4
4
Открытые противоречия
2
1
Задокументированные нежелательные явления
2
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between BPC-157 and Thymosin Beta-4?
- BPC-157 is classified as "Заживление", while Thymosin Beta-4 is classified as "Заживление". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, BPC-157 or Thymosin Beta-4?
- The highest available evidence level is "Модель на животных" for BPC-157 and "Исследование на людях" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of BPC-157 and Thymosin Beta-4 in Germany and the United States?
- Германия: BPC-157 — Не одобрено, Thymosin Beta-4 — Не одобрено. США: BPC-157 — Только для исследований, Thymosin Beta-4 — Не одобрено. These are factual summaries with source and review date on the individual pages.